ZURICH (Reuters) - Swiss drugmaker Novartis AG has proposed changes to European prescribing information for its Galvus diabetes medicine, after finding safety problems with higher doses.Novartis made the recommendations after giving a safety update to European regulators and said on Tuesday it would also discuss the data and recommendations with other regulators.
